Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 10/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 0.70 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.70 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.70 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.70 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.70 |
| ▸ | CDK1 | P06493 | 2/20 | 0.70 |
| ▸ | PIM1 | P11309 | 2/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.70 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.70 |
| ▸ | CDK2 | P24941 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.70 |
| ▸ | GSK3A | P49840 | 2/20 | 0.70 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.70 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.70 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.70 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.70 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4243638 | 0.91 | CDC7 (1.00) | CDC7GSK3BCDK5DYRK1AROCK2 | |
| SCHEMBL385584 | 0.83 | CDC7 (1.00) | CDC7GSK3BCDK5DYRK1AROCK2 | |
| SCHEMBL14748141 | 0.82 | CDC7 (0.70) | CDC7GSK3BCDK5DYRK1AROCK2 | |
| SCHEMBL4240964 | 0.81 | CDC7 (0.82) | CDC7GSK3BCDK5DYRK1AROCK2 | |
| SCHEMBL4243686 | 0.78 | CDC7 (1.00) | CDC7GSK3BCDK5DYRK1AROCK2 | |
| SCHEMBL4241465 | 0.78 | CDC7 (1.00) | CDC7GSK3BCDK5DYRK1AROCK2 | |
| SCHEMBL18441097 | 0.76 | CDC7 (0.60) | CDC7GSK3BCDK5DYRK1AROCK2 | |
| SCHEMBL4236999 | 0.76 | CDC7 (1.00) | CDC7GSK3BCDK5DYRK1AROCK2 | |
| SCHEMBL384971 | 0.75 | CDC7 (0.60) | CDC7GSK3BPIM1CSNK2A1KDM4E | |
| SCHEMBL4245493 | 0.75 | CDC7 (1.00) | CDC7GSK3BCDK5DYRK1AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074114-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2010521-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | Novartis Ag (CH) | 2009-01-07 | — | — | EP | claimed |
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| WO-2007124288-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | claimed |
| EP-2074114-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2074114-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007124288-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | CDC7, CDC37, CDC73 | CDC7 1/4885GSK3B 1106/4885CDK5 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.